{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:05:12Z","timestamp":1753891512941,"version":"3.41.2"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Cardiovascular diseases represent the leading cause of mortality worldwide. This category includes cerebrovascular disease, ischemic heart disease, and peripheral vascular disease. Secondary prevention is effective for patients with a history of cardiovascular events, with antihypertensives, statins, and acetylsalicylic acid being the most prescribed drugs. Therapeutic adherence is crucial, as the lack of it increases morbidity, mortality, reduces quality of life, and raises healthcare costs. However, less than half of patients adhere to all three drugs within the first year post-event. Furthermore, non-adherence is more pronounced in primary care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>Based on our hypothesis that in patients undergoing cardiovascular secondary prevention, an intervention grounded in the application of the Chronic Care Model improves adherence to the three preventive drugs, this study aims to evaluate the efficacy of a health education intervention, which implements this model, to increase adherence in patients with cardiovascular disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An open-label randomized controlled trial will be conducted, selecting patients who meet inclusion criteria through consecutive non-probability sampling. Random assignment will be performed using the random number table method. Based on a therapeutic adherence rate of 50% in the control group and 80% in the intervention group, with a type I error of 5% (95% confidence interval), a type II error of 20% (80% power), and accounting for a 15% loss to follow-up, the final sample size will be of 45 patients per group. Follow-up will last for 1\u202fyear. Following data collection, univariate, bivariate, and multivariate analyses will be performed to isolate confounding factors and assess the intervention\u2019s impact on adherence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>If the results obtained in this study are favorable and the intervention is successful in enhancing therapeutic adherence, its applicability would be substantial, representing a feasible intervention for implementation in primary care. This approach addresses a significant public health issue, namely the lack of therapeutic adherence and its associated consequences. Moreover, this is particularly pertinent for high-risk patients, such as those in secondary prevention, given that cardiovascular disease remains the leading cause of mortality in developed countries. This trial has been registered at <jats:uri>clinicalTrials.gov<\/jats:uri>, <jats:uri>https:\/\/clinicaltrials.gov\/study\/NCT06510946<\/jats:uri>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1510744","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T07:57:14Z","timestamp":1736236634000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of an intervention to increase therapeutic adherence in patients with secondary prevention for cardiovascular disease: a study protocol for a randomized controlled trial"],"prefix":"10.3389","volume":"11","author":[{"given":"Francisco Manuel","family":"Lid\u00f3n-Mu\u00f1oz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"Quesada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente Francisco","family":"Gil-Guill\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domingo","family":"Orozco-Beltr\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"year":"2003","key":"ref1","article-title":"Organizaci\u00f3n Panamericana de la Salud 2004. Adherencia a los tratamientos a largo plazo: pruebas para la acci\u00f3n"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"first-page":"2003","volume-title":"Adherence to long term therapies: Evidence for action","year":"2004","key":"ref3"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.medcli.2018.05.011","article-title":"The burden of disease in Spain: results from the global burden of disease 2016","volume":"151","author":"Soriano","year":"2018","journal-title":"Med Clin (Barc)"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.jacc.2022.11.001","article-title":"Global burden of cardiovascular diseases and risks collaboration, 1990\u20132021","volume":"80","author":"Lindstrom","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.amjmed.2011.12.013","article-title":"Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients","volume":"125","author":"Naderi","year":"2012","journal-title":"Am J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ijcard.2019.05.071","article-title":"Number of drugs used in secondary cardiovascular prevention and late survival in the population of Valencia community","volume":"293","author":"Red\u00f3n","year":"2019","journal-title":"Spain Int J Cardiol"},{"volume-title":"Adherencia terap\u00e9utica en hipertensi\u00f3n arterial en la farmacia comunitaria [master's thesis]","year":"2012","author":"Perseguer","key":"ref8"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"CD007768","DOI":"10.1002\/14651858.CD007768.pub3","article-title":"Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews","volume":"2022","author":"Ryan","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S0214-9168(08)72574-9","article-title":"Cumplimiento terap\u00e9utico en pacientes con enfermedad cardiovascular","volume":"20","author":"De Frutos","year":"2008","journal-title":"Clin Invest Arterioscl"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1056\/NEJMoa2208275","article-title":"Polypill strategy in secondary cardiovascular prevention","volume":"387","author":"Castellano","year":"2022","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0002-9343(97)00467-1","article-title":"Compliance with treatment regimens in chronic asymptomatic diseases","volume":"102","author":"Miller","year":"1997","journal-title":"Am J Med"},{"volume-title":"Una aproximaci\u00f3n multidisciplinar al problema de la adherencia terap\u00e9utica en las enfermedades cr\u00f3nicas: estado de la situaci\u00f3n y perspectivas de futuro [Internet]. Spain","year":"2012","author":"Conthe","key":"ref13"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2307\/3350391","article-title":"Organizing Care for Patients with chronic illness","volume":"74","author":"Wagner","year":"1996","journal-title":"Milbank Q"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2049-3258-72-37","article-title":"Adherence influencing factors a systematic review of systematic reviews","volume":"72","author":"Mathes","year":"2014","journal-title":"Arch Public Health"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/HJH.0000000000000382","article-title":"Differences in cardiovascular disease risk when antihypertensive medication adherence is assessed by pharmacy fill versus self-report: the cohort study of medication adherence among older adults (CoSMO)","volume":"33","author":"Krousel-Wood","year":"2015","journal-title":"J Hypertens"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1510744\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T07:57:17Z","timestamp":1736236637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1510744\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":17,"alternative-id":["10.3389\/fmed.2024.1510744"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1510744","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"article-number":"1510744"}}